TIDMERGO
RNS Number : 2665I
Ergomed plc
16 June 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
Ergomed strengthens executive team with appointment of Dr Dan
Weng as CEO
- Founder Dr Miroslav Reljanovic to become Executive
Vice-Chairman
London, UK - 16 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or
'the Company'), a company dedicated to the provision of specialised
services to the pharmaceutical industry and the development of new
drugs, today announces the strengthening of its executive team with
the appointment of Dr Dan Weng as its new Chief Executive Officer
and a Board Director of Ergomed. Dr Weng joins Ergomed with effect
from 1 July 2017 from EPS Holdings, Inc. ('EPSHD'), a global CRO
listed on the Tokyo Stock Exchange.
When Dr Weng joins the Company, Dr Miroslav Reljanovic,
Ergomed's founder, will transition from CEO to Executive
Vice-Chairman, where he will support Dr Weng and the Board in
growing and developing Ergomed's CRO offering and provide strategic
guidance on Ergomed's co-development business and wholly-owned
pipeline.
Dr Weng has extensive experience in managing and growing CRO
businesses, including nearly six years at EPS International Holding
Co. ("EPSI"), subsidiary of EPSHD, where he was Chairman, President
and CEO. During his tenure at EPSI, Dr Weng oversaw significant
growth, both organically and through M&A in Asia, the US and
Europe, with revenues increasing over five-fold. Dr Weng's
background covers multiple therapeutic areas, supporting all stages
of development through to approval. He was also a Board Director of
EPSHD and had an active role in corporate strategy and investor
relations.
Prior to this, Dr Weng has a proven track record with 20 years
of delivering growth in executive positions at international CROs
including MedPace, Icon Clinical Research, PharmaNet and Quintiles,
where he established the offering in China.
Dr Weng qualified as a medical doctor at Tongji Medical
University, China, and holds an MA in Health Planning, Policy and
Management from the University of Leeds, UK. He also held research
positions at Harvard Medical School - Massachusetts General
Hospital and the University of California.
Dr Miroslav Reljanovic, Chief Executive Officer of Ergomed,
said: "Ergomed has a history of innovation in clinical research and
development and this is set to continue. I'm very pleased to
welcome Dan to the team to guide Ergomed forward as we seek to
build on the strong growth of our CRO and pharmacovigilance
businesses. I look forward to contributing to Ergomed's continued
success as Vice-Chairman, focusing on our existing and future
co-development deals, our pipeline products, and the broader
strategy of the business."
Peter George, Chairman of Ergomed, said: "Dan has significant
experience in growing CRO businesses globally, and is an ideal
addition to the Ergomed team. With the increasing maturity and
scale of the business, his international experience in corporate
development across all the areas of clinical research make for an
excellent fit.
"Miro's inspiration, innovation and drive have grown Ergomed to
the public company that it is today. I'd like to thank Miro for all
that he has done to-date as Founder and CEO. We look forward to him
fully dedicating himself to the continued strategic development of
the Company as Executive Vice-Chairman, working alongside Dan."
Dr Dan Weng, Chief Executive Officer designate of Ergomed, said:
"Ergomed is a pioneer in the development of novel clinical
outsourcing services where its site management and study physician
support approach differentiates it from competitors. It is also
taking a leadership position in the provision of pharmacovigilance
services and is showing very strong growth in that part of the
business. I look forward to joining what is an excellent team and
contributing to further growth and success."
Dr Dan Weng, aged 54, has held the following directorship in the
past five years: EPS Holdings, Inc.
Ergomed confirms that there are no further disclosures to be
made in relation to Rule 17 of paragraph (g) of Schedule Two of the
AIM Rules for Companies in respect of Dr Weng's appointment.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0)
1483 503205
Miroslav Reljanovic (Chief Executive
Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consilium-comms.com
Elliott / Ivar Milligan
MC-Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed acquired a pipeline of proprietary development products for
the treatment of surgical bleeding. For further information, visit:
http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAAKSFFPXEAF
(END) Dow Jones Newswires
June 16, 2017 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024